Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases.
Geoffrey Yuet Mun WongConnie I DiakosThomas J HughMark P MolloyPublished in: International journal of molecular sciences (2022)
Colorectal liver metastases (CRLM) are the leading cause of death among patients with metastatic colorectal cancer (CRC). As part of multimodal therapy, liver resection is the mainstay of curative-intent treatment for select patients with CRLM. However, effective treatment of CRLM remains challenging as recurrence occurs in most patients after liver resection. Proposed clinicopathologic factors for predicting recurrence are inconsistent and lose prognostic significance over time. The rapid development of next-generation sequencing technologies and decreasing DNA sequencing costs have accelerated the genomic profiling of various cancers. The characterisation of genomic alterations in CRC has significantly improved our understanding of its carcinogenesis. However, the functional context at the protein level has not been established for most of this genomic information. Furthermore, genomic alterations do not always result in predicted changes in the corresponding proteins and cancer phenotype, while post-transcriptional and post-translational regulation may alter synthesised protein levels, affecting phenotypes. More recent advancements in mass spectrometry-based technology enable accurate protein quantitation and comprehensive proteomic profiling of cancers. Several studies have explored proteomic biomarkers for predicting CRLM after oncologic resection of primary CRC and recurrence after curative-intent resection of CRLM. The current review aims to rationalise the proteomic complexity of CRC and explore the potential applications of proteomic biomarkers in CRLM.
Keyphrases
- liver metastases
- mass spectrometry
- copy number
- label free
- single cell
- metastatic colorectal cancer
- prognostic factors
- protein protein
- rectal cancer
- small molecule
- circulating tumor
- ejection fraction
- liquid chromatography
- amino acid
- newly diagnosed
- end stage renal disease
- gene expression
- high resolution
- squamous cell carcinoma
- healthcare
- ms ms
- prostate cancer
- high throughput
- chronic pain
- high performance liquid chromatography
- minimally invasive
- combination therapy
- liquid chromatography tandem mass spectrometry
- gas chromatography
- heat shock
- health information
- human health
- robot assisted
- free survival
- replacement therapy
- solid phase extraction
- circulating tumor cells
- heat stress